Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)

Bruce R. Blazar, William J Murphy

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Haematopoietic stem cell transplantation (HSCT) offers promise for the treatment of haematological and immune disorders, solid tumours, and as a tolerance inducing regimen for organ transplantation. Allogeneic HSCTs engraftment requires immunosuppression and the anti-tumour effects are dependent upon the immune effector cells that are contained within or generated from the donor graft. However, significant toxicities currently limit its efficacy. These problems include: (i) graft-versus-host disease (GVHD) in which donor T cells attack the recipient resulting in multi-organ attack and morbidity, (ii) a profound period of immune deficiency following HSCT, and (iii) donor graft rejection. Currently available methods to prevent or treat GVHD with systemic immunosuppression can lead to impaired immune recovery, increased opportunistic infections, and higher relapse rates. This review will provide an overview of GVHD pathophysiology and discuss the roles of various cells, pathways, and factors in the GVHD generation process and in the preservation of graft-versus-tumour effects. Variables that need to be taken into consideration in attempting to extrapolate preclinical results to the clinical paradigm will be highlighted.

Original languageEnglish (US)
Pages (from-to)1747-1767
Number of pages21
JournalPhilosophical Transactions of the Royal Society B: Biological Sciences
Volume360
Issue number1461
DOIs
StatePublished - Sep 29 2005
Externally publishedYes

Fingerprint

Transplantation (surgical)
bone marrow transplant
transplantation
immunosuppression
Graft vs Host Disease
Bone Marrow Transplantation
Grafts
bone
cell transplantation
Bone
tumor
neoplasms
Hematopoietic Stem Cell Transplantation
Immunosuppression
organ transplantation
graft rejection
Tumors
relapse
pathophysiology
Transplants

Keywords

  • Allogeneic
  • Bone marrow transplantation
  • Cytokines
  • Graft versus leukaemia
  • Graft-versus-host disease

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Agricultural and Biological Sciences (miscellaneous)

Cite this

Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). / Blazar, Bruce R.; Murphy, William J.

In: Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. 360, No. 1461, 29.09.2005, p. 1747-1767.

Research output: Contribution to journalArticle

@article{46139ff3e58c466e9c61bb6046c6086e,
title = "Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)",
abstract = "Haematopoietic stem cell transplantation (HSCT) offers promise for the treatment of haematological and immune disorders, solid tumours, and as a tolerance inducing regimen for organ transplantation. Allogeneic HSCTs engraftment requires immunosuppression and the anti-tumour effects are dependent upon the immune effector cells that are contained within or generated from the donor graft. However, significant toxicities currently limit its efficacy. These problems include: (i) graft-versus-host disease (GVHD) in which donor T cells attack the recipient resulting in multi-organ attack and morbidity, (ii) a profound period of immune deficiency following HSCT, and (iii) donor graft rejection. Currently available methods to prevent or treat GVHD with systemic immunosuppression can lead to impaired immune recovery, increased opportunistic infections, and higher relapse rates. This review will provide an overview of GVHD pathophysiology and discuss the roles of various cells, pathways, and factors in the GVHD generation process and in the preservation of graft-versus-tumour effects. Variables that need to be taken into consideration in attempting to extrapolate preclinical results to the clinical paradigm will be highlighted.",
keywords = "Allogeneic, Bone marrow transplantation, Cytokines, Graft versus leukaemia, Graft-versus-host disease",
author = "Blazar, {Bruce R.} and Murphy, {William J}",
year = "2005",
month = "9",
day = "29",
doi = "10.1098/rstb.2005.1701",
language = "English (US)",
volume = "360",
pages = "1747--1767",
journal = "Philosophical Transactions of the Royal Society B: Biological Sciences",
issn = "0800-4622",
publisher = "Royal Society of London",
number = "1461",

}

TY - JOUR

T1 - Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)

AU - Blazar, Bruce R.

AU - Murphy, William J

PY - 2005/9/29

Y1 - 2005/9/29

N2 - Haematopoietic stem cell transplantation (HSCT) offers promise for the treatment of haematological and immune disorders, solid tumours, and as a tolerance inducing regimen for organ transplantation. Allogeneic HSCTs engraftment requires immunosuppression and the anti-tumour effects are dependent upon the immune effector cells that are contained within or generated from the donor graft. However, significant toxicities currently limit its efficacy. These problems include: (i) graft-versus-host disease (GVHD) in which donor T cells attack the recipient resulting in multi-organ attack and morbidity, (ii) a profound period of immune deficiency following HSCT, and (iii) donor graft rejection. Currently available methods to prevent or treat GVHD with systemic immunosuppression can lead to impaired immune recovery, increased opportunistic infections, and higher relapse rates. This review will provide an overview of GVHD pathophysiology and discuss the roles of various cells, pathways, and factors in the GVHD generation process and in the preservation of graft-versus-tumour effects. Variables that need to be taken into consideration in attempting to extrapolate preclinical results to the clinical paradigm will be highlighted.

AB - Haematopoietic stem cell transplantation (HSCT) offers promise for the treatment of haematological and immune disorders, solid tumours, and as a tolerance inducing regimen for organ transplantation. Allogeneic HSCTs engraftment requires immunosuppression and the anti-tumour effects are dependent upon the immune effector cells that are contained within or generated from the donor graft. However, significant toxicities currently limit its efficacy. These problems include: (i) graft-versus-host disease (GVHD) in which donor T cells attack the recipient resulting in multi-organ attack and morbidity, (ii) a profound period of immune deficiency following HSCT, and (iii) donor graft rejection. Currently available methods to prevent or treat GVHD with systemic immunosuppression can lead to impaired immune recovery, increased opportunistic infections, and higher relapse rates. This review will provide an overview of GVHD pathophysiology and discuss the roles of various cells, pathways, and factors in the GVHD generation process and in the preservation of graft-versus-tumour effects. Variables that need to be taken into consideration in attempting to extrapolate preclinical results to the clinical paradigm will be highlighted.

KW - Allogeneic

KW - Bone marrow transplantation

KW - Cytokines

KW - Graft versus leukaemia

KW - Graft-versus-host disease

UR - http://www.scopus.com/inward/record.url?scp=33644821494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644821494&partnerID=8YFLogxK

U2 - 10.1098/rstb.2005.1701

DO - 10.1098/rstb.2005.1701

M3 - Article

C2 - 16147539

AN - SCOPUS:33644821494

VL - 360

SP - 1747

EP - 1767

JO - Philosophical Transactions of the Royal Society B: Biological Sciences

JF - Philosophical Transactions of the Royal Society B: Biological Sciences

SN - 0800-4622

IS - 1461

ER -